Thomas Decaens

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol et al. · Nature · 2021 · 1.2K citations · Full text

Life Sciences, Immunology, Oncology +17

Liver Transplantation for Hepatocellular Carcinoma: A Model Including α-Fetoprotein Improves the Performance of Milan Criteria

Christophe Duvoux, Françoise Roudot‐Thoraval, Thomas Decaens et al. · Gastroenterology · 2012 · 941 citations · Full text

Medicine, Oncology, Pathology +13

Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

Philip J. Johnson, Shukui Qin, Joong‐Won Park et al. · Journal of Clinical Oncology · 2013 · 775 citations · Full text

Medicine, Oncology, Pharmacology +14

Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study

Josep M. Llovet, Thomas Decaens, Jean‐Luc Raoul et al. · Journal of Clinical Oncology · 2013 · 596 citations · Full text

Medicine, Oncology, Pharmacology +13

Apc Tumor Suppressor Gene Is the “Zonation-Keeper” of Mouse Liver

Samira Benhamouche, Thomas Decaens, Cécile Godard et al. · Developmental Cell · 2006 · 526 citations · Full text

Medicine, Genetics, Molecular Genetics +16